Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

NCT07412470 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07412470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07412470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients
Lead sponsor
Sanofi
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 13, 2026
Completion date
August 15, 2033
Enrollment
526 (estimated)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection